ID
37356
Beskrivning
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form is to be filled in continously during the study and/or at the follow-up evaluation and contains information on other medication the participant has received during the course of the study.
Länk
https://clinicaltrials.gov/ct2/show/NCT00996840
Nyckelord
Versioner (1)
- 2019-07-20 2019-07-20 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
20 juli 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Concomitant Medications
- StudyEvent: ODM
Beskrivning
Concomitant Medications
Alias
- UMLS CUI-1
- C2347852
Beskrivning
Sequence Number
Datatyp
text
Alias
- UMLS CUI [1]
- C2348184
Beskrivning
Trade Name preferred
Datatyp
text
Alias
- UMLS CUI [1]
- C2360065
Beskrivning
[hidden]
Datatyp
text
Alias
- UMLS CUI [1]
- C2826819
Beskrivning
[hidden]
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C0871468
Beskrivning
[hidden]
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0013227
- UMLS CUI [1,2]
- C1516698
- UMLS CUI [1,3]
- C0805701
Beskrivning
[hidden]
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C0805701
- UMLS CUI [1,2]
- C0231175
Beskrivning
Unit Dose
Datatyp
text
Alias
- UMLS CUI [1]
- C0869039
Beskrivning
Concomitant Medication Units
Datatyp
integer
Alias
- UMLS CUI [1,1]
- C1519795
- UMLS CUI [1,2]
- C2347852
Beskrivning
Concomitant Medication Frequency
Datatyp
text
Alias
- UMLS CUI [1,1]
- C3476109
- UMLS CUI [1,2]
- C2347852
Beskrivning
Concomitant Medication Route
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0013153
- UMLS CUI [1,2]
- C2347852
Beskrivning
Reason for Medication
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0392360
- UMLS CUI [1,2]
- C0013227
Beskrivning
Start Date and Time
Datatyp
datetime
Alias
- UMLS CUI [1]
- C3897500
Beskrivning
Concomitant Medication Taken Prior to Study?
Datatyp
boolean
Alias
- UMLS CUI [1]
- C2826667
Beskrivning
If no, specify End Date and Time
Datatyp
boolean
Alias
- UMLS CUI [1]
- C2826666
Beskrivning
End date and time
Datatyp
datetime
Alias
- UMLS CUI [1]
- C3899266
Similar models
Concomitant Medications
- StudyEvent: ODM
C1264639 (UMLS CUI [1,2])
C0871468 (UMLS CUI [1,2])
C1516698 (UMLS CUI [1,2])
C0805701 (UMLS CUI [1,3])
C0231175 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])